Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Invested Capital (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Invested Capital for 9 consecutive years, with $346.5 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Invested Capital fell 34.36% year-over-year to $346.5 million, compared with a TTM value of $346.5 million through Jun 2025, down 34.36%, and an annual FY2024 reading of $427.3 million, up 283.34% over the prior year.
  • Invested Capital was $346.5 million for Q2 2025 at Autolus Therapeutics, down from $371.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $582.0 million in Q1 2024 and bottomed at $111.5 million in Q4 2023.
  • Average Invested Capital over 5 years is $318.6 million, with a median of $298.7 million recorded in 2022.
  • The sharpest move saw Invested Capital plummeted 62.68% in 2023, then soared 283.34% in 2024.
  • Year by year, Invested Capital stood at $313.3 million in 2021, then dropped by 4.67% to $298.7 million in 2022, then tumbled by 62.68% to $111.5 million in 2023, then skyrocketed by 283.34% to $427.3 million in 2024, then fell by 18.92% to $346.5 million in 2025.
  • Business Quant data shows Invested Capital for AUTL at $346.5 million in Q2 2025, $371.1 million in Q1 2025, and $427.3 million in Q4 2024.